Inclusion Criteria:

1. Male, aged ≥18 years;

2. ECOG (Eastern Cooperative Oncology Group) 0-1, expected survival of ≥ 3 months;

3. Histology or cytology confirmed adenocarcinoma of the prostate;

4. Radiological evidence of metastatic bone or soft tissue lesions;

5. Ongoing medical castration or previous surgical castration;

6. Testosterone at castration level during screening;

7. Prior to screening, subjects with evidence of disease progression while receiving
ADT (androgen deprivation therapy);

8. Had progressed on at least one novel endocrine therapy, and had progressed on at
least one taxane-based chemotherapy (or those who are intolerant or refuse
chemotherapy);

9. The functional level of organs must meet the requirements.

Exclusion Criteria:

1. Subjects with known hypersensitivity to the active ingredient or excipients of
HSK46575 Tablets;

2. Subjects who have received any antitumor therapy within 4 weeks (or 5 half-lives,
whichever is shorter) prior to the first dose; or treatment with nitrosoureas,
bicalutamide, or nilutamide within 6 weeks (or 5 half-lives, whichever is shorter)
prior to the first dose;

3. Subjects whose toxicity from prior anticancer therapy remains > Grade 1 before the
first dose;

4. Subjects who have used strong or moderate CYP3A4 inhibitors or inducers, CYP2C9
sensitive substrates, and OCT2 or MATE1 substrates within 14 days or 5 half-lives
prior to the first dose of the investigational drug, whichever is longer;

5. Subjects who have undergone Grade 3-4 surgery;

6. Subjects who plan to receive any other antitumor therapy during the study ;

7. Subjects with active metastases to central nervous system;

8. Subjects with serious bone damage caused by prostate cancer bone metastasis as
assessed by the investigators;

9. Within 6 months before the first dose, subjects had concurrent pituitary or adrenal
dysfunction;

10. Subjects with uncontrolled hypertension;

11. Subjects with central nervous system disorders such as epilepsy and multiple
sclerosis;

12. Subjects with active cardiac disease within 6 months prior to the first dose, or a
history of arterial or venous thromboembolism;

13. Subjects with a QTc interval prolongation to >470 ms during the screening period
calculated by the Fridericia formula；

14. Subjects with a history of other malignancies;

15. Subjects with a history of immunodeficiency;

16. Subjects with active HBV, HCV, or syphilis infection;

17. Subjects who have participated in other clinical studies within 4 weeks before the
first dose;

18. Other conditions.